1. Home
  2. ZURA vs NNAVW Comparison

ZURA vs NNAVW Comparison

Compare ZURA & NNAVW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZURA
  • NNAVW
  • Stock Information
  • Founded
  • ZURA 2022
  • NNAVW 2007
  • Country
  • ZURA United States
  • NNAVW United States
  • Employees
  • ZURA 30
  • NNAVW N/A
  • Industry
  • ZURA Biotechnology: Biological Products (No Diagnostic Substances)
  • NNAVW Industrial Machinery/Components
  • Sector
  • ZURA Health Care
  • NNAVW Industrials
  • Exchange
  • ZURA Nasdaq
  • NNAVW Nasdaq
  • Market Cap
  • ZURA 76.6M
  • NNAVW N/A
  • IPO Year
  • ZURA N/A
  • NNAVW N/A
  • Fundamental
  • Price
  • ZURA $1.23
  • NNAVW $4.50
  • Analyst Decision
  • ZURA Buy
  • NNAVW
  • Analyst Count
  • ZURA 7
  • NNAVW 0
  • Target Price
  • ZURA $14.67
  • NNAVW N/A
  • AVG Volume (30 Days)
  • ZURA 401.0K
  • NNAVW 53.1K
  • Earning Date
  • ZURA 05-08-2025
  • NNAVW 03-12-2025
  • Dividend Yield
  • ZURA N/A
  • NNAVW N/A
  • EPS Growth
  • ZURA N/A
  • NNAVW N/A
  • EPS
  • ZURA N/A
  • NNAVW N/A
  • Revenue
  • ZURA N/A
  • NNAVW $4,963,000.00
  • Revenue This Year
  • ZURA N/A
  • NNAVW N/A
  • Revenue Next Year
  • ZURA N/A
  • NNAVW N/A
  • P/E Ratio
  • ZURA N/A
  • NNAVW N/A
  • Revenue Growth
  • ZURA N/A
  • NNAVW 43.44
  • 52 Week Low
  • ZURA $0.97
  • NNAVW $4.47
  • 52 Week High
  • ZURA $6.35
  • NNAVW $4.70
  • Technical
  • Relative Strength Index (RSI)
  • ZURA 49.62
  • NNAVW N/A
  • Support Level
  • ZURA $1.06
  • NNAVW N/A
  • Resistance Level
  • ZURA $1.32
  • NNAVW N/A
  • Average True Range (ATR)
  • ZURA 0.15
  • NNAVW 0.00
  • MACD
  • ZURA 0.01
  • NNAVW 0.00
  • Stochastic Oscillator
  • ZURA 68.42
  • NNAVW 0.00

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Share on Social Networks: